:


Castello , Coci A, Magrini U. Paraneoplastic marrow alterations in patients with cancer. Haematologica 1992; 77:392.

Chapman JF, et al. Guidelines on the clinical use of leucocyte- depleted blood components. Transfus Med 1998; 8:59.

Clagett GP, et al. Prevention of venous thromboembolism. Chest 1995; 108 (Suppl):312.

Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8:73.

Jannssens AM, Offner FC, Van Hove WZ. Bone marrow necrosis. Cancer 2000; 88:1769.

Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumor angiogenesis. Lancet Oncol 2001; 2:608.

Prandoni P, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484.

Rickles FR. Relationship of blood clotting and tumor angiogenesis. Hae- mostasis 2001; 31 (Suppl 1):16.

Rizzo J D, et al. Use of epoetin in patients with cancer: evidence- based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083, and Blood 2002; 100:2303.

Ruf W. Molecular regulation of blood clotting in tumor biology. Haemosta- sis 2001; 31 (Suppl 1):5.

Sallah S, et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86:828.

Sorenson HT, et al. The risk of a diagnosis of cancer after primary deep vein thrombosis or pulmonary embolism. N Engl J Med 1998; 338:1169.

Tas F, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25:371.

Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu Paris 1865; 3:94.

Weitz 1, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein resistance due to Factor V Leiden. Cancer 1997; 79:2024.

: